评估高正常血压患者主要不良心血管事件(药物治疗对比饮食控制)的随机开放标签平行临床试验设计与原理:PRINT-TAHA9试验
PRINT-TAHA9是一项单中心随机开放标签对照平行试验,拟纳入1620例18岁及以上、收缩压130-140 mmHg、舒张压低于90 mmHg且ASCVD风险评分超过7.5%的成人,比较氨氯地平/缬沙坦加低盐低脂饮食与单纯饮食对MACE的影响,随访3年。
要点
- 指南推荐高正常血压且10年ASCVD风险升高者启动降压治疗,但缺乏直接证据支持其预防MACE。
- 试验纳入收缩压130-140 mmHg、舒张压低于90 mmHg且ASCVD风险评分超过7.5%的成人。
- 治疗组接受氨氯地平/缬沙坦及低盐低脂饮食,对照组接受类似饮食,每6个月随访一次。
核心结论
- 尽管指南推动对血压升高进行早期治疗,但由于缺乏此类干预能显著减少MACE发生的充分证据,争论仍在继续;本试验旨在填补这一关键证据空白。
研究设计与样本
- PRINT-TAHA9为单中心、随机、开放标签、对照、平行临床研究,计划纳入1620例18岁及以上成人。
- 入组标准为收缩压130-140 mmHg、舒张压低于90 mmHg且ASCVD风险评分超过7.5%。
- 研究分五个阶段执行,每阶段入组300至400名参与者。
- 参与者随机分配至治疗组(接受氨氯地平/缬沙坦及低盐低脂饮食)或对照组(接受类似饮食)。
- 随访每6个月一次,持续3年,监测血压、评估用药依从性、记录不良事件并按需调整干预。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The distinction between normal and high blood pressure remains a debated topic, with varying guidelines on when to start medication. Contemporary guidelines advocate for the initiation of antihypertensive therapy in individuals who present with high-normal blood pressure, particularly those exhibiting elevated 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores. Despite these recommendations, there is a notable lack of direct evidence supporting the efficacy of treating high-normal blood pressure to prevent major adverse cardiovascular events (MACE). METHODS: The PRINT-TAHA9 trial, a unicentric, randomized, open-label, controlled, parallel clinical study, seeks to explore the effects of intensive blood pressure control on MACE in participants with high-normal blood pressure. We will enroll 1620 adults aged 18 years and above with a systolic blood pressure range of 130-140 mmHg, diastolic blood pressure under 90 mmHg, and atherosclerotic cardiovascular disease (ASCVD) risk score exceeding 7.5%. The study will be executed in five distinct phases, with each phase enrolling between 300 and 400 participants. Participants will be randomly assigned to either the treatment group receiving antihypertensive medication (amlodipine/valsartan) and a low-salt/low-fat diet or to the control group receiving a similar diet. Follow-up visits are scheduled every 6 months over a 3-year period to monitor blood pressure, evaluate medication adherence, document any adverse events, and adjust the intervention as necessary. Cox proportional hazards regression analysis will be employed to examine the disparities between the two arms. DISCUSSION: Despite guidelines promoting early treatment of elevated blood pressure, the debate continues due to insufficient evidence that such interventions significantly reduce the occurrence of MACE. This trial seeks to address this critical evidence gap. TRIAL REGISTRATION: The PRINT-TAHA9 trial was registered in October 2019 with the Iranian Registry of Clinical Trials (IRCT.ir) under the registration number IRCT20191002044961N1. https://irct.behdasht.gov.ir/trial/43092 .
引用
- Attar A, Mirhosseini SA, Borazjani R, et al. Design and rationale for a randomized, open-label, parallel clinical trial evaluating major adverse cardiovascular events (pharmacological treatment versus diet control) in patients with high-normal blood pressure: the PRINT-TAHA9 trial. Trials. 2024. PMID: 39187881. doi:10.1186/s13063-024-08420-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。